It will be important to validate our findings in other CDCP1/Src-driven cancer types that are also reliant on OXPHOS for disease progression such as prostate, melanoma, and colorectal, amongst others [4, 5, 79, 94–97]. This evidence concerns the gene SRC and melanoma.